NCT04631562 - Study of ALXN1820 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Healthy

Interventions

DRUG

ALXN1820 SC

ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.

DRUG

ALXN1820 IV

ALXN1820 IV (450 mg) will be administered as an IV infusion.

DRUG

Placebo SC

Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.

DRUG

Placebo IV

Placebo IV will be administered as an IV infusion.

Trial Locations (3)

4006

Research Site, Herston

SE1 1YR

Research Site, London

SE5 9RS

Research Site, London